Literature DB >> 15671039

Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.

Akihiro Ohashi1, Malgorzata Z Zdzienicka, Junjie Chen, Fergus J Couch.   

Abstract

The BRCA2 breast cancer tumor suppressor is involved in the repair of double strand breaks and broken replication forks by homologous recombination through its interaction with DNA repair protein Rad51. Cells defective in BRCA2.FANCD1 are extremely sensitive to mitomycin C (MMC) similarly to cells deficient in any of the Fanconi anemia (FA) complementation group proteins (FANC). These observations suggest that the FA pathway and the BRCA2 and Rad51 repair pathway may be linked, although a functional connection between these pathways in DNA damage signaling remains to be determined. Here, we systematically investigated the interaction between these pathways. We show that in response to DNA damage, BRCA2-dependent Rad51 nuclear focus formation was normal in the absence of FANCD2 and that FANCD2 nuclear focus formation and mono-ubiquitination appeared normal in BRCA2-deficient cells. We report that the absence of BRCA2 substantially reduced homologous recombination repair of DNA breaks, whereas the absence of FANCD2 had little effect. Furthermore, we established that depletion of BRCA2 or Rad51 had a greater effect on cell survival in response to MMC than depletion of FANCD2 and that depletion of BRCA2 in FANCD2 mutant cells further sensitized these cells to MMC. Our results suggest that FANCD2 mediates double strand DNA break repair independently of Rad51-associated homologous recombination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671039     DOI: 10.1074/jbc.M414669200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  DNA crosslinking damage and cancer - a tale of friend and foe.

Authors:  Yaling Huang; Lei Li
Journal:  Transl Cancer Res       Date:  2013-06       Impact factor: 1.241

Review 2.  Molecular pathogenesis of Fanconi anemia.

Authors:  Natalie Collins; Gary M Kupfer
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

3.  Fanconi anemia proteins and endogenous stresses.

Authors:  Qishen Pang; Paul R Andreassen
Journal:  Mutat Res       Date:  2009-07-31       Impact factor: 2.433

4.  BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork.

Authors:  David T Long; Vladimir Joukov; Magda Budzowska; Johannes C Walter
Journal:  Mol Cell       Date:  2014-09-11       Impact factor: 17.970

5.  Genomic instability in mice is greater in Fanconi anemia caused by deficiency of Fancd2 than Fancg.

Authors:  Ramune Reliene; Mitsuko L Yamamoto; P Nagesh Rao; Robert H Schiestl
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

Review 6.  Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.

Authors:  Larry H Thompson; John M Hinz
Journal:  Mutat Res       Date:  2009-02-21       Impact factor: 2.433

7.  FANCM and FAAP24 maintain genome stability via cooperative as well as unique functions.

Authors:  Yucai Wang; Justin W Leung; Yingjun Jiang; Megan G Lowery; Huong Do; Karen M Vasquez; Junjie Chen; Weidong Wang; Lei Li
Journal:  Mol Cell       Date:  2013-01-17       Impact factor: 17.970

8.  Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway.

Authors:  Monika Aggarwal; Taraswi Banerjee; Joshua A Sommers; Chiara Iannascoli; Pietro Pichierri; Robert H Shoemaker; Robert M Brosh
Journal:  Cancer Res       Date:  2013-07-18       Impact factor: 12.701

Review 9.  BRCA-FA pathway as a target for anti-tumor drugs.

Authors:  Rachel Litman; Rigu Gupta; Robert M Brosh; Sharon B Cantor
Journal:  Anticancer Agents Med Chem       Date:  2008-05       Impact factor: 2.505

Review 10.  The Fanconi anemia protein interaction network: casting a wide net.

Authors:  Meghan A Rego; Frederick W Kolling; Niall G Howlett
Journal:  Mutat Res       Date:  2008-12-03       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.